deltamethrin
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 17, 2020 (NCT04566510)
Timeline
No events for the selected filters.
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)[C@H](C(=O)O[C@H](C#N)c2cccc(Oc3ccccc3)c2)[C@@H]1C=C(Br)Br- Mol. weight
- 505.21 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1593566 ↗
Also known as
- (1r-(1 alpha(s*),3 alpha))-3-(2,2-dibromoethenyl)-2,2-dimethylcyclopropanecarboxylic acid, cyano(3-phenoxyphenyl)methyl ester
- alpha-cyano-3-phenoxybenzyl (1r,3r)-cis-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropanecarboxylate
- butox
- decamethrin
- decamethrin
- decamethrin
- decamethrin
- decamethrin
- decamethrin
- decamethrin, (1r-(1alpha(r*),3alpha))-isomer
- decamethrin, (1r-(1alpha(r*),3beta))-isomer
- decamethrin, (1r-(1alpha(s*),3beta))-isomer
- decamethrin, (1s-(1alpha(r*),3alpha))-isomer
- decamethrin, (1s-(1alpha(s*),3alpha))-isomer
- decamethrine
- decis
- decistab
- deltamethrin
- deltamethrin
- deltamethrin
- deltamethrin
- difexon
- k-othrin
- nrdc 161
- oms 1998
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04566510 | N/A | Oct 17, 2020 | National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco, University of London |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2020 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1